Pharmacologic reperfusion therapy for acute myocardial infarction.
Acute myocardial infarction (MI) remains a significant problem in terms of morbidity, mortality and healthcare costs. Pharmacologic reperfusion therapies for MI are becoming increasingly complex. This review therefore places contemporary pharmacologic MI developments into perspective. An historical overview of pharmacologic reperfusion therapy for MI is provided, followed by an analysis of current limitations, treatment options, and present and likely future pharmacologic therapies. Adjunctive percutaneous and other treatments are also discussed, to clarify what is becoming a rapidly changing field.
Lowe
Harry C
HC
Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Neill
Briain D Mac
BD
Van de Werf
Frans
F
Jang
Ik-Kyung
IK
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D015425:Myocardial Reperfusion / Q000379:methods*
D005343:Fibrinolytic Agents